<DOC>
	<DOC>NCT01101048</DOC>
	<brief_summary>The purpose of this study is to assess the safety, tolerability, and potential immune response of AMG 167 following multiple subcutaneous (SC, injection under the skin) dose administrations in healthy men and postmenopausal women with low bone mineral density.</brief_summary>
	<brief_title>An Ascending Multiple Dose Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<criteria>Low bone mineral density as determined at the time of screening [as defined by bone mineral density (BMD) Tscores of the lumbar spine (L1L4), or total evaluable vertebrae (if fewer than L1L4); or femoral neck between 1.0 and 2.5, exclusive] 25hydroxyvitamin D ≥ 20 ng/mL Willing and able to take ≥ 1,000 mg elemental calcium and ≥ 800 IU (but ≤ 1,000 IU) vitamin D daily upon enrollment Osteoporosis, as defined by BMD Tscores of the lumbar spine (L1L4) or total evaluable vertebrae (if fewer than L1L4); or femoral neck ≤ 2.5 History of vertebral fracture, or fragility fracture (a fracture resulting from no or minor trauma; ie, fall from standing height or less) of the wrist, humerus, hip, or pelvis after age 50 Diagnosed with any condition that will affect bone metabolism Diagnosis of clotting factor deficiency or history of bleeding or coagulation disorder History of spinal stenosis History of facial nerve paralysis Exclusion Criteria for Cohort 7 Substudy (Transition to Alendronate): Contraindicated or intolerant of alendronate therapy</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Bone Mineral Density</keyword>
</DOC>